Peptide vaccine shows promise in head and neck cancer trial, but study halted early
NCT ID NCT04445064
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This study tested a peptide-based immunotherapy given before surgery to people with head and neck cancer. The goal was to see if the vaccine could boost the immune system to fight the tumor. Only 17 people took part before the study was stopped early. The main focus was on safety and immune response, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Conditions
Explore the condition pages connected to this study.